Catch Potential Mishaps With Mayzent for Advanced Multiple Sclerosis

May 2020

Mayzent (siponimod) will be a new oral med for adults with an advanced form of multiple sclerosis (MS).

About half of patients with relapsing-remitting MS will develop worsening symptoms within 10 years...called secondary progressive multiple sclerosis.

Expect Mayzent to be saved for patients who progress despite other multiple sclerosis treatments (interferon beta, etc).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Practice Be Creative to Help Patients Get Their Meds
Infectious Diseases Stay Alert for Hydroxychloroquine Rxs to Prevent or Treat COVID-19
Shortages Minimize the Impact of Drug Shortages
Generics Be Ready for New Advair Diskus Generics
Practice Enhance Patient Care During COVID-19 and Beyond
Infectious Diseases Stop the Spread of Misinformation About Meds and Supplements for COVID-19
Mental Health Watch for Signs of Distress in Patients or Colleagues
Insomnia Prevent Common Mix-Ups With Sleep Meds
Multiple Sclerosis Catch Potential Mishaps With Mayzent for Advanced Multiple Sclerosis